logo
Twitter
Discord
Email
logo
Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals, Inc.

NASDAQ•RYTM
CEO: Dr. David P. Meeker M.D.
Sector: Healthcare
Industry: Biotechnology
Listing Date: 2017-10-09
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Contact Information
222 Berkeley Street, 12th Floor, Boston, MA, 02116, United States
857-264-4280
rhythmtx.com
Market Cap
$7.53B
P/E (TTM)
-37.8
40.9
Dividend Yield
--
52W High
$122.20
52W Low
$45.91
52W Range
88%
Rank68Top 92.8%
1.7
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 1.7 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2015-2024

Financial Dashboard

Q3 2025 Data

Revenue

$51.30M+54.27%
4-Quarter Trend

EPS

-$0.82+15.49%
4-Quarter Trend

FCF

-$26.62M+5.58%
4-Quarter Trend

2025 Q3 Earnings Highlights

Key Highlights

Product Revenue Soars 56% Net product revenue reached $137.5M for nine months, driven by increased sales volume across geographies.
Operating Loss Significantly Narrows Loss from operations improved 35% to $(145.0)M, reflecting lower R&D spending versus prior year.
R&D Costs Drop 36% R&D expense fell to $125.3M, primarily due to non-recurrence of IPR&D acquisition costs from 2024.
Strong Cash Position Maintained Cash and short-term investments totaled $416.1M as of September 30, 2025, supporting operations for over 24 months.

Risk Factors

Need for Future Capital Continued operating losses require substantial future funding; failure to secure capital delays development or commercialization efforts.
IMCIVREE Market Acceptance Commercial success hinges on achieving broad coverage and adequate reimbursement from payors globally.
Regulatory Approval Uncertainty Future regulatory submissions, like the sNDA for acquired hypothalamic obesity, face inherent delays or adverse decisions.
IP Protection Challenges Patent validity and enforceability remain uncertain; competitors may develop non-infringing alternative technologies.

Outlook

Advance Next-Gen Agonists Plan to complete RM-718 Phase 1 enrollment Q1 2026; initiate pivotal Phase 3 for bivamelagon in 2026.
Expand Global Commercialization Continue building sales infrastructure in Europe and pursuing market access in additional countries.
Awaiting Key FDA Decision Expect FDA decision on sNDA for acquired hypothalamic obesity by PDUFA date of December 20, 2025.
Manage Operating Expenses Expect SG&A to increase supporting expanded commercialization and ongoing clinical trial costs.

Peer Comparison

Revenue (TTM)

Kiniksa Pharmaceuticals International, plcKNSA
$597.97M
+55.7%
Arvinas, Inc.ARVN
$312.30M
+93.9%
Protagonist Therapeutics, Inc.PTGX
$209.22M
-35.4%

Gross Margin (Latest Quarter)

Viridian Therapeutics, Inc.VRDN
100.0%
+8043.1pp
Syndax Pharmaceuticals, Inc.SNDX
95.4%
-4.6pp
Rhythm Pharmaceuticals, Inc.RYTM
89.3%
+0.8pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
RVMD$15.58B-15.9-49.2%7.0%
RNA$9.48B-20.5-33.5%0.4%
NUVL$7.69B-20.0-39.5%0.0%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
7.0%
Steady Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
0%
Cash Flow Needs Attention

Research & Insights

Next earnings:Feb 25, 2026
|
EPS:-$0.79
|
Revenue:-
Reports
All Years

  • Form 10-Q - Q3 2025

    Period End: Sep 30, 2025|Filed: Nov 4, 2025|
    Revenue: $51.30M+54.3%
    |
    EPS: $-0.82+15.5%
    Miss

  • Form 10-Q - Q2 2025

    Period End: Jun 30, 2025|Filed: Aug 5, 2025|
    Revenue: $48.50M+66.8%
    |
    EPS: $-0.75+41.5%
    Miss

  • Form 10-Q - Q1 2025

    Period End: Mar 31, 2025|Filed: May 7, 2025|
    Revenue: $32.70M+25.9%
    |
    EPS: $-0.81-65.5%
    Miss

  • Form 10-K - FY 2024

    Period End: Dec 31, 2024|Filed: Feb 28, 2025|
    Revenue: $130.13M+68.1%
    |
    EPS: $-4.34-35.6%
    Miss

  • Form 10-Q - Q3 2024

    Period End: Sep 30, 2024|Filed: Nov 6, 2024|
    Revenue: $33.25M+47.8%
    |
    EPS: $-0.71-6.6%
    Beat

  • Form 10-Q/A - Q2 2024

    Period End: Jun 30, 2024|Filed: Aug 14, 2024|
    Revenue: $29.08M+51.3%
    |
    EPS: $-0.53-35.4%
    Beat

  • Form 10-Q - Q2 2024

    Period End: Jun 30, 2024|Filed: Aug 6, 2024|Refer to amended data

  • Form 10-Q - Q1 2024

    Period End: Mar 31, 2024|Filed: May 7, 2024|
    Revenue: $25.97M+126.4%
    |
    EPS: $-2.35+158.2%
    Meet